The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
Understanding of ROS-Inducing Strategy in Anticancer Therapy
Open accessAbstract
Redox homeostasis is essential for the maintenance of diverse cellular processes. Cancer cells have higher levels of reactive oxygen species (ROS) than normal cells as a result of hypermetabolism, but the redox balance is maintained in cancer cells due to their marked antioxidant capacity. Recently, anticancer therapies that induce oxidative stress by increasing ROS and/or inhibiting antioxidant processes have received significant attention. The acceleration of accumulative ROS disrupts redox homeostasis and causes severe damage in cancer cells. In this review, we describe ROS-inducing cancer therapy and the anticancer mechanism employed by prooxidative agents. To understand the comprehensive biological response to certain prooxidative anticancer drugs such as 2-methoxyestradiol, buthionine sulfoximine, cisplatin, doxorubicin, imexon, and motexafin gadolinium, we propose and visualize the drug-gene, drug-cell process, and drug-disease interactions involved in oxidative stress induction and antioxidant process inhibition as well as specific side effects of these drugs using pathway analysis with a big data-based text-mining approach. Our review will be helpful to improve the therapeutic effects of anticancer drugs by providing information about biological changes that occur in response to prooxidants. For future directions, there is still a need for pharmacogenomic studies on prooxidative agents as well as the molecular mechanisms underlying the effects of the prooxidants and/or antioxidant-inhibitor agents for effective anticancer therapy through selective killing of cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Polazzi, E., Mengoni, I., Caprini, M., Peña-Altamira, E., Kurtys, E., & Monti, B. (2013) · Neurosignals · doi:10.1159/000337115 · Cited by 8,994
ROS function in redox signaling and oxidative stress
Schieber, M., & Chandel, N. S. (2014) · Current Biology · doi:10.1016/j.cub.2014.03.034 · Cited by 6,931 · cited 1×
“A mild level of ROS regulates cell development and homeostasis, whereas a high level inflicts severe cellular damage [50, 51].”
BackgroundCisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Trachootham, D., Alexandre, J., & Huang, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2803 · Cited by 5,452 · cited 3×
“Adaptation to excessive ROS conditions in cancer cells has been reported, suggesting they have a higher level of antioxidative capacity and ROS than normal cells [2].”
BackgroundMetals, Toxicity and Oxidative Stress
Valko, M., Morris, H., & Cronin, M. (2005) · Current Medicinal Chemistry · doi:10.2174/0929867053764635 · Cited by 5,018 · cited 1×
“As previously demonstrated, the impairment of redox homeostasis mediated by an excess of oxidized biological molecules is associated with cellular toxic effects [12].”
BackgroundCancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681 · cited 1×
“Accordingly, increased drug efflux through the transporter leads to drug resistance [119].”
BackgroundOxidative stress: oxidants and antioxidants
Sies, H. (1997) · Experimental Physiology · doi:10.1113/expphysiol.1997.sp004024 · Cited by 4,566
Modulation of oxidative stress as an anticancer strategy
Gorrini, C., Harris, I. S., & Mak, T. W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4002 · Cited by 3,579
Oxidative stress: a concept in redox biology and medicine
Sies, H. (2015) · Redox Biology · doi:10.1016/j.redox.2015.01.002 · Cited by 2,991
Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer
Timmerman, R. (2010) · JAMA · doi:10.1001/jama.2010.261 · Cited by 2,532
Cited by
Reactive Oxygen Species Signaling and Oxidative Stress: Transcriptional Regulation and Evolution
Hong, Y., Boiti, A., Vallone, D., & Foulkes, N. S. (2024) · Antioxidants · doi:10.3390/antiox13030312 · Cited by 696
Oxidative Stress in the Tumor Microenvironment and Its Relevance to Cancer Immunotherapy
Aboelella, N. S., Brandle, C., Kim, T., Ding, Z.-C., & Zhou, G. (2021) · Cancers · doi:10.3390/cancers13050986 · Cited by 286
Sadiq, I. Z. (2023) · Current Molecular Medicine · doi:10.2174/1566524022666211222161637 · Cited by 263
Metabolic impairment of non-small cell lung cancers by mitochondrial HSPD1 targeting
Parma, B., Ramesh, V., Gollavilli, P. N., Siddiqui, A., Pinna, L., Schwab, A., Marschall, S., Zhang, S., Pilarsky, C., Napoli, F., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02049-8 · Cited by 46
Targeting autophagy enhances atezolizumab-induced mitochondria-related apoptosis in osteosarcoma
Liu, Z., Wang, H., Hu, C., Wu, C., Wang, J., Hu, F., Fu, Y., Wen, J., & Zhang, W. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03449-6 · Cited by 45
Nasrollahzadeh, A., Momeny, M., Fasehee, H., Yaghmaie, M., Bashash, D., Hassani, S., Mousavi, S. A., & Ghaffari, S. H. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2021.119087 · Cited by 20
Metadata
- Authors
- Kim, S. J., Kim, H. S., & Seo, Y. R.
- Venue
- Oxidative Medicine and Cellular Longevity
- Publisher
- Wiley
- Published
- 2019-12-20
- Volume
- 2019
- Pages
- 1-12
- ISSN
- 1942-0994 (ISSN-L)
- 1942-0900
- OpenAlex
- W2995708286
- Cited by
- 406
- References
- 112
- FWCI
- 13.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.